Brilacidin

Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin

Retrieved on: 
Tuesday, October 4, 2022
OTCQB, CAS, Â, Brilacidin, GLOBE, Mucormycosis, Toxicity, Cryptococcus neoformans, Mycosis, Mortality, Human, Review, Mycology, Cryptococcus, Research, Disease, Cryptococcosis, Aspergillosis, Antifungal, Patent, 50, Calcineurin, VOR, Caspofungin, Drug resistance, Molecular biology, Candidiasis, Orphan drug, William DeGrado, Aspergillus fumigatus, Patient, Voriconazole, POSA, Canker, Preprint, University, HIV/AIDS, Pharmaceutical industry, Vaccine, Aspergillus, Mucorales

A Host Defense Peptide Mimetic, Brilacidin, Potentiates Caspofungin Antifungal Activity Against Human Pathogenic Fungi.

Key Points: 
  • A Host Defense Peptide Mimetic, Brilacidin, Potentiates Caspofungin Antifungal Activity Against Human Pathogenic Fungi.
  • Following an in vitro drug screening of 1,402 compounds, Brilacidin showed promising antifungal activity and was subsequently selected for additional pre-clinical evaluation, including in combination with caspofungin (CAS), voriconazole (VOR), and posaconazole (POSA), all current antifungal treatments.
  • Further in vitro testing showed Brilacidin synergized with CAS in C. albicans, C. auris and C. neoformans.
  • Pivotal clinical trials for antifungal drugs are generally smaller than those in other infectious disease areas, requiring between 300 and 600 patients.

Omnix Medical Starts Phase I Clinical Trial of Novel Anti-Infective; First Healthy Volunteers Dosed

Retrieved on: 
Tuesday, April 12, 2022
AMR, Pharmacokinetics, Clinical trial, Mortality, Acinetobacter baumannii, Bacteria, Research, Publication, CSO, QIDP, EIC, IIA, CEO, Prevalence, HIA, Technology, NIH, Gram-negative bacteria, Cell membrane, Infection, H2020, Mall of America, Patient, Brilacidin, Pharmaceutical industry, Vaccine

JERUSALEM, Israel, April 12, 2022 -- Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since March 28, 2022, six healthy volunteers have been administered the novel antimicrobial, which is based on a naturally occuring mechanism of action (MoA) leading to a targeted, effective destruction of the cell membrane of pathogens. The trial is being conducted in Groningen, The Netherlands. OMN6 is being evaluated in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of single and repeat IV infusion of the compound in healthy subjects. Results are expected by Q4, 2022.

Key Points: 
  • JERUSALEM, Israel, April 12, 2022 -- Omnix Medical , a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6.
  • OMN6 is being evaluated in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of single and repeat IV infusion of the compound in healthy subjects.
  • Dr. Niv Bachnoff, CSO of Omnix Medical, added We are thrilled about the progress of our first clinical trial.
  • Omnix Medical was founded on 2015 to address the urgent unmet need for new life-saving anti-infective drugs.

Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research

Retrieved on: 
Monday, August 2, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Brilacidin, Variants of SARS-CoV-2, Severe acute respiratory syndrome coronavirus, COVID-19, Antiviral drug, Severe acute respiratory syndrome

WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Companys defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.

Key Points: 
  • WAKEFIELD, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provided an update on ongoing antiviral research of Brilacidin, the Companys defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.
  • Brilacidin SARS-CoV-2 Manuscript: Scientists conducting laboratory testing of Brilacidin, in particular its ability to block entry of SARS-CoV-2 into human cells, have submitted their research findings for peer-review publication.
  • These data include insights into Brilacidins antiviral mechanisms of action and Brilacidin activity against the Alpha (B.1.1.7) and Gamma (P.1) SARS-CoV-2 variants.
  • Taken together, the results from ongoing lab research into Brilacidins antiviral properties by different groups of scientists only strengthens our belief in Brilacidin, said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals.

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium

Retrieved on: 
Friday, June 18, 2021
Coronaviridae, Sarbecovirus, Health sciences, Medicine, Zoonoses, Antiviral drugs, COVID-19 pandemic in Russia, Coronavir, Severe acute respiratory syndrome, Brilacidin, COVID-19

The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.

Key Points: 
  • The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
  • The presentation on Brilacidin will be part of the Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases Breakout Session.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19

Retrieved on: 
Thursday, June 3, 2021
Health sciences, Health, Chemical compounds, Clinical research, Pharmaceutical industry, Brilacidin, Guanidines, Pyrimidines, Pyrrolidines, Clinical trial, COVID-19, Casirivimab/imdevimab

WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).

Key Points: 
  • WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).
  • Innovation Pharmaceuticals is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
  • Complete trial enrollment comprised 120 dosed patients recruited across multiple sites.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Retrieved on: 
Tuesday, June 1, 2021
Medicine, Clinical medicine, Health sciences, Omadacycline, Infectious diseases, Antibiotics, Pneumonia, Intravenous therapy, Infection, Brilacidin, Amoxicillin

The approval of an oral-only dose regimen for NUZYRA in pneumonia represents a significant opportunity to offer clinicians the ability to treat patients in either the outpatient or primary care setting.

Key Points: 
  • The approval of an oral-only dose regimen for NUZYRA in pneumonia represents a significant opportunity to offer clinicians the ability to treat patients in either the outpatient or primary care setting.
  • The availability of an oral-only dosing regimen of NUZYRA in pneumonia helps address a significant gap for an effective, safe and well-tolerated oral antibiotic in the primary care setting.
  • The Companys lead commercial product, NUZYRA (omadacycline), is an oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
  • NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

Retrieved on: 
Thursday, May 27, 2021
Health sciences, Health, Chemical compounds, Antibiotics, Brilacidin, Guanidines, Pyrimidines, Pyrrolidines, Clinical research, Clinical trial, COVID-19

WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Companys 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.

Key Points: 
  • WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Companys 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.
  • Innovation Pharma is developing Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients under U.S. FDA Fast Track designation (see NCT04784897 ).
  • The Company intends to provide an update to shareholders upon the final patients entering the trial.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.

Innovation Pharma Files Form 10-Q; Patient Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19 Tops 70 Percent

Retrieved on: 
Thursday, May 13, 2021
Medical specialties, Clinical medicine, Medicine, Abdominal pain, Colitis, Diarrhea, Ulcerative colitis, Mucositis, Brilacidin

Alfasigma has placed an order with the Company for Brilacidin drug substance needed for the trial, which the Company is in the process of supplying.

Key Points: 
  • Alfasigma has placed an order with the Company for Brilacidin drug substance needed for the trial, which the Company is in the process of supplying.
  • \xe2\x80\x9cPatient enrollment in the Phase 2 study of Brilacidin for COVID-19 is moving along quickly, far faster in recruitment than other COVID-19 studies we\xe2\x80\x99ve seen in industry reports.
  • Development work related to the formulation and manufacture of Brilacidin in capsule form is underway to support our Phase 2 trial in Ulcerative Colitis planned to commence this year.
  • Additional work tied to starting, in 2022, a planned Phase 3 study of Brilacidin in Oral Mucositis is also in progress.

Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19

Retrieved on: 
Wednesday, April 28, 2021
Health sciences, Health, Medicine, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, Brilacidin, Antiviral drug, COVID-19 drug repurposing research

\xe2\x80\x9cWe are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral.

Key Points: 
  • \xe2\x80\x9cWe are hopeful Brilacidin will emerge not only as an effective COVID-19 therapeutic, but also as a desperately needed broad spectrum antiviral.
  • We look forward to completing our COVID-19 clinical trial and releasing topline results.\xe2\x80\x9d\nLinked below are recent articles published in the journal Nature.
  • Can drugmakers finally do the right thing?\nInnovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and currently is enrolling patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).
  • Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.

Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients

Retrieved on: 
Monday, April 5, 2021
Chemical compounds, Food and Drug Administration, Antibiotics, Brilacidin, Guanidines, Pyrimidines, Pyrrolidines, Health, Life sciences, Fast track

Upon reaching 25 percent enrollment (30 subjects), recruitment was paused and a pre-specified unblinded safety data review and evaluation was conducted by the DMC.

Key Points: 
  • Upon reaching 25 percent enrollment (30 subjects), recruitment was paused and a pre-specified unblinded safety data review and evaluation was conducted by the DMC.
  • Efficacy data was not reviewed by the DMC and remains blinded.
  • Trial data for Veklury could serve as a benchmark in evaluating Brilacidin outcomes.
  • Innovation Pharma is developing Brilacidin, a defensin-mimetic, under Fast Track designation from the U.S. Food and Drug Administration (FDA).